Global Influenza Drug Market
Global influenza drug market is expected to reach USD 14,223,755.18 thousand by 2031 from USD 8,730,345.60 thousand in 2023, at the CAGR of 6.5% in the forecast period of 2024 to 2031.
Market Segmentation: Global Influenza Drug Market, By Type (Influenza A, Influenza B, and Influenza C), Treatment (Vaccine and Drugs), Route of Administration (Oral, Intramuscular, Intradermal, Intranasal, and Intravenous), Age (Pediatrics and Adults), End User (Hospitals, and Home Care), Distribution Channel (Direct Tenders and Retail Sales), Country (U.S., Canada and Mexico, China, Japan, India, Australia, South Korea, Thailand, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, Rest of Europe, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and Rest of South America)- Industry Trends & Forecast to 2031
Some of the major factors contributing to the growth of the global influenza drug market are:
• Increasing prevalence rate of influenza
• Government initiatives and vaccination programs
• Advancements in medical research and technology
Market Players:
The key market players for global influenza drug market listed below: • Ambu A/S
• GSK plc.
• Sanofi S.A.
• CSL,
• Astrazeneca Plc
• F. Hoffmann-La Roche Ltd
• Viatris Inc.,
• Abbott
• Amneal Pharmaceuticals LLC.
• AbbVie Inc
• BioCryst Pharmaceuticals Inc.
• Lupin
• Zydus Pharmaceuticals, Inc.
• Macleods Pharmaceuticals Ltd.
• Viatris Inc.
• DAIICHI SANKYO COMPANY
• LIMITED, Cipla Inc.
• Shionogi & Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• NATCO Pharma Limited
• Alvogen
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.